PROGRESS-AD Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease Sponsor GlaxoSmithKline Clinical Trial Phase II Status Currently recruiting Drug GSK4527226
15-AVP-786-303 Extension STUDY Long term, extension study of the safety and efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AVP-786
AB21004 Masitinib in patients with mild to moderate Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor AB Science Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Masitinib
ACP-204-006 ACP-204 in adults with Alzheimer's disease psychosis Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor ACADIA Pharmaceuticals Clinical Trial Phase III Status Currently recruiting Drug ACP-204
ADEPT-1 A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer's disease dementia Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Karuna Therapeutics Clinical Trial Phase III Status Currently recruiting Drug KarXT
ADEPT-3 Open-label extension study to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Karuna Therapeutics Clinical Trial Phase III Status Enrolling by invitation Drug KarXT (combines xanomeline with trospium)
AUTONOMY A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Janssen Research & Development Clinical Trial Phase II Status Ongoing studies but not recruiting Drug JNJ-63733657
Brochures: AD and Related Diseases- Symptoms Evolution Diagnosis Treatments Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
By your side fighting dementia Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
CAFCA Effect of caffeine on cognition in Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor University Hospital, Lille Clinical Trial Phase III Status Currently recruiting Drug Caffeine
CELIA A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Biogen Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BIIB080
CHOLINE-2 Donepezil versus non-drug treatment in Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Assistance Publique - Hôpitaux de Paris Clinical Trial Phase III Status Currently recruiting Drug Donepezil
Clarity AD A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Eisai Clinical Trial Phase III Status Ongoing studies but not recruiting Drug BAN2401
DNLI-H-0001 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy participants and participants with Frontotemporal Dementia (FTD-GRN) Sponsor Denali Therapeutics Inc. Clinical Trial Phase II Status Currently recruiting Drug DNL593
evoke evoke - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
evoke+ evoke+ - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
GABRIELLA A clinical trial to look at how well RO7269162 works in people who are at risk of Alzheimer’s disease or who have mild cognitive impairment due to Alzheimer’s disease and how safe RO7269162 is at different doses At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Hoffmann-La Roche Clinical Trial Phase II Status Currently recruiting Drug RO7269162
IL-2-AD Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Centre Hospitalier St Anne Clinical Trial Phase II Status Currently recruiting Drug IL-2 (PROLEUKIN ®)
INFRONT-3 A Phase 3 study to evaluate efficacy and safety of AL001 in frontotemporal dementia Frontotemporal dementia Sponsor Alector Inc. Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AL001
MINDFul A Study of XPro1595 in patients with early Alzheimer's disease with biomarkers of inflammation Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Immune Bio Clinical Trial Phase II Status Ongoing studies but not recruiting Drug XPro1595
Neflamapimod An open-label Phase 2a clinical study of the P38 alpha kinase inhibitor neflamapimod in patients with dementia with Lewy Bodies Dementia with Lewy Bodies Sponsor Eip Pharma Clinical Trial Phase II Status Enrolling by invitation Drug Neflamapimod
POLARIS-AD Phase 3, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease Sponsor AriBio Co Clinical Trial Phase III Status Currently recruiting Drug AR1001
Preventing carer exhaustion Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
PROCLAIM Phase 1/2 clinical trial of LY3884963 in patients with frontotemporal dementia with progranulin mutations Frontotemporal dementia Sponsor Prevail Therapeutics Clinical Trial Phase II Status Currently recruiting Drug LY3884963
Reτain A Study of JNJ-64042056 in participants with preclinical Alzheimer's disease At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Sponsor Janssen Pharmaceutica N.V., Belgium Clinical Trial Phase II Status Currently recruiting Drug JNJ-64042056
TOGETHER A study to test the efficacy, safety, and tolerability of bepranemab in patients with mild cognitive impairment or mild Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor UCB Biopharma SRL Clinical Trial Phase II Status Ongoing studies but not recruiting Drug Bepranemab (also called UCB0107)
TPN-101 A Phase 2a study of TPN-101 in patients with C9ORF72 ALS/FTD Frontotemporal dementia Sponsor Transposon Therapeutics, Inc. Clinical Trial Phase II Status Ongoing studies but not recruiting Drug TPN-101
